Impact of Anticholinergic Antihypertensive Treatment Duration on Dementia Risk

Overview

This study emulated a target trial using UK CPRD data to assess how varying durations of antihypertensive drugs with anticholinergic properties (AC AHT) affect the risk of vascular dementia and Alzheimer’s disease. Longer treatment (>6 years) was associated with a modestly reduced 10-year risk of vascular dementia but showed no significant effect on Alzheimer’s disease risk. The study highlights the importance of target trial emulation to avoid bias in observational research on treatment duration effects.

Background

Anticholinergic (AC) drugs, which block acetylcholine neurotransmission, are widely used for various conditions and have known short-term cognitive side effects. Their long-term impact on dementia risk remains unclear, especially for AC antihypertensive drugs (AC AHT) that have weak anticholinergic effects but are commonly prescribed in older adults. Hypertension itself is a risk factor for vascular dementia, and AC drugs may influence Alzheimer’s disease risk through cholinergic pathways. Evaluating treatment duration effects using real-world data is challenging due to survival bias, which this study addressed by emulating a target trial design.

Data Highlights

Key Findings

• Longer duration (>6 years) of AC AHT treatment was associated with a 31% reduction in 10-year risk of vascular dementia compared to ≤3 years.
• No significant association was found between treatment duration and Alzheimer’s disease risk.
• Intermediate treatment duration (3-6 years) showed no significant effect on either dementia type compared to ≤3 years.
• Naïve observational analyses that did not emulate a target trial yielded implausible beneficial effects, highlighting potential bias.
• Target trial emulation effectively addressed immortal time bias and treatment-confounder feedback in this observational study.

Clinical Implications

Clinicians should consider that longer-term use of antihypertensive drugs with anticholinergic properties may modestly reduce vascular dementia risk, potentially through better hypertension control. However, no clear benefit or harm was observed for Alzheimer’s disease risk. Careful assessment of anticholinergic burden remains important, and target trial emulation methods can improve the validity of observational drug safety studies.

Conclusion

Emulating a target trial demonstrated that prolonged treatment with AC AHT drugs modestly lowers vascular dementia risk without significantly affecting Alzheimer’s disease risk. This approach provides a robust framework to evaluate treatment duration effects while minimizing bias.

References

1. Original Study -- Impact of Varying Treatment Durations with Antihypertensive Medications Exhibiting Anticholinergic Properties on Dementia Risk